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Abstract. The effects of 4 h haemodialysis (15 patients) or
4h haemofiltration (five patients) on plasma concen-
trations of atrial natriuretic peptide (ANP) were com-
pared by means of a sensitive radioreceptor binding assay,
and related to accompanying changes in body weight,
blood pressure and plasma renin activity. Before dialysis,
plasma ANP concentrations were considerably elevated:
haemodialysis group 10-484 pmol/1 (mean 156pmol/l);
haemofiltration group 72-320 pmol/1 (mean 170pmol/l).
Although plasma concentrations of ANP fell markedly
with treatment in both groups: post-haemodialysis
2-187 pmol/1 (mean 67 pmol/1); post-haemofiltration
47-135 pmol/1 (mean 79 pmol/1), after treatment it
remained above the normal range in 14 of the 20 patients.
Pretreatment plasma ANP was related to systolic blood
pressure (r — 0.459; P<0.05) but bore no relationship to
mean or diastolic blood pressure, or plasma renin activity.
The fall in plasma ANP concentration during treatment
correlated with the postural blood pressure drop after
dialysis (r = 0.505; P < 0.05), but was unrelated to changes
in weight or plasma renin activity with haemodialysis
or haemofiltration. Plasma ANP concentrations rose
rapidly again in the 60min after dialysis treatment,
without change in body weight.
These results show that high levels of biologically active
ANP circulate in end-stage renal disease. The fact that
these are not reduced to normal by haemodialysis or
haemofiltration, despite restoration to normovolaemic or
hypovolaemic state, suggests that the increased levels
of ANP in end-stage renal failure are due to both
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hypervolaemia and other factors, which may include
occult cardiac dysfunction and loss of renal clearance.
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Introduction
The primary stimulus for the cardiac release of atrial
natriuretic peptide (ANP) is increased stretch of atrial
myocytes [1], which is usually a consequence of increased
atrial pressure due to either increased circulating plasma
volume [2,3] or to congestive heart failure [4]. Several
studies employing radioimmunoassay have confirmed
that plasma concentrations of immunoreactive ANP are
considerably elevated in patients with end-stage renal
disease [5-10] and may be reduced by haemodialysis [6,7]
or ultrafiltration [7,8,10]. The conclusion has been drawn
that raised concentrations of ANP in end-stage renal dis-
ease are entirely due to plasma volume overload [5,10],
which may be corrected by dialysis or ultrafiltration.
However, the kidney is an important site of ANP clear-
ance [11], and ANP may be metabolised in the renal
tubule [12], in common with other peptide hormones [13].
Furthermore, cardiac function is often impaired in
patients with renal failure, even when overt clinical
cardiac failure is not apparent [14].
It is possible, therefore, that loss of normal renal clear-
ance and occult cardiac dysfunction might account in part
for the elevated plasma concentrations of ANP in end-
stage renal disease. It is also unclear whether the high
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plasma concentrations of immunoreactive ANP reported
in renal failure truly represent biologically active peptides,
as apparent elevations of peptide hormones in end-stage
renal disease may be due to immunoreactive circulating
peptide fragments. We have therefore measured plasma
concentrations of ANP in patients with end-stage renal
disease, employing a sensitive and specific radioreceptor
assay for ANP, which detects intact biologically active
peptide [15]. The changes in plasma ANP produced by
haemodialysis and haemofiltration have been compared,
and related to degree of volume depletion after dialysis
assessed by weight change, postural blood pressure fall,
and change in plasma renin activity.
Materials and Methods
Patients and Protocol '
Twenty patients were studied, 15 aged 41-68 years (mean
55 years) undergoing conventional haemodialysis and five
patients aged 49-71 years (mean 55 years) treated by
haemofiltration. A description of the patients is given in
Table 1. There were no significant differences in pre-
dialysis weight, blood pressure (measured by mercury
sphygmomanometer) or plasma renin activity. No patient
had clinical evidence of cardiac failure. All were taking
phosphate binders; for hypertension two haemodialysis
and three haemofiltration patients were receiving
beta-blockers, and three haemodialysis patients and one
haemofiltration patient were receiving nifedipine.
Tablet. Patient data
Patients (F:M)
Mean age (range) years
Aetiology
glomerulonephritis
pyelonephritis
analgesic
polycystic
hypertension
Predialysis
weight (kg)
mean BP (mmHg)
PRA (ng/ml per h)
Haemodialysis
15(14:1)
55(41-68)
1
4
5
3
2
7O±5
101 ±4
7.3 ±2.3
Haemofiltration
5 (4:1)
55(49-71)
2
1
2
65 + 7
107 ±5
12.5 ±6.8
All patients were treated for 4 h, at the same time of
day. They remained supine and did not eat or drink during
treatment. Haemodialysis was carried out (15 patients)
using a Gambro AK-10 machine and Gambro GF-120 H
capillary dialysers. Haemofiltration was performed using
a Gambro haemofiltration module and Gambro F-88
haemofilter. The dialysate contained; acetate 35 mmol/1;
Na+ 135 mmol/1; K+ l^t mmol/1; Ca2+ 1.625 mmol/1;
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Mg2 + 0.25 mmol/1. The haemofiltration substitution sol-
ution contained lactate 35 mmol/1; Na + 136 mmol/1; K + 0
or 2 mmol/1; Ca2+ 2 mmol/1 and Mg2+ 1.0 mmol/1. Body
weight and supine and standing blood pressure (diastolic
phase 5) were measured immediately before and at the end
of the treatment period. At the commencement and termi-
nation of dialysis treatment, 4-6 ml blood samples were
drawn from the arterial dialysis line into chilled tubes
containing EDTA with the addition of aprotinin (0.1 mg/
ml) for measurement of ANP, and into chilled tubes con-
taining EDTA for the measurement of plasma renin
activity. Three haemodialysis patients were studied again
on a second day, when blood for ANP measurement was
taken before dialysis, after 30min and after 180 min
dialysis treatment, and again 60 min after treatment had
ended.
After immediate centrifugation at 4°C, plasma was
stored at — 20°C until ANP measurement, which was
carried out by a radioreceptor assay described in detail
elsewhere [4,15], after extraction of ANP from plasma by
means of Sep-pak C18 cartridges. In brief, the radiorecep-
tor assay involves competition of endogenous ANP in
plasma, or alpha-human ANP standard, with a synthetic
24-amino acid radioligand (123I tyr0atriopeptin II) for
ANP receptors in bovine adrenal cortex membranes.
Assay tubes contained 50 ul of plasma extract resus-
pended in assay buffer, in a total volume of 200 ul, and
were incubated at 25°C for 60 min, after which bound and
free radioligands were separated by rapid-filtration assay
with use of Whatman GF/C glass-fibre filters, whose
radioactivity was measured in a gamma counter. The
detection limit of the assay was 0.6 fmol per tube, intra-
assay CV was 8.2% and inter-assay CV was 10.1%.
Plasma ANP concentrations were corrected for recovery
during the extraction procedure. Plasma renin activity
was measured by radioimmunoassay [16].
All patients gave informed consent to the study, which
was approved by the Hospital Ethical Committee. Results
are expressed as mean + SEM. Statistical comparisons
were made using the Wilcoxon test for paired data, and
linear regression was by the method of least squares.
Results
In comparison with plasma ANP concentrations
measured by radioreceptor assay in healthy controls
(17 + SD 13 pmol/1; « = 60) [4], plasma ANP concentra-
tions before dialysis treatment were consistently elevated
in both the haemodialysis patients (10-484 pmol/1) and
haemofiltration patients (72-320 pmol/1). The plasma
peptide concentration fell significantly during treatment
to a similar extent in both groups (Fig. 1; haemodialysis
from 156 to 67 pmol/1; P< 0.01, haemofiltration from 170
to 79 pmol/1; /><0.05). Weight loss was 2.2 ±0.2 kg
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during haemodialysis treatment and 1.8+0.3 kg during
haemofiltration. Plasma renin activity increased during
treatment, from 7.3 ±2.3 to 13.1 ±4.7 ng/ml per h in
haemodialysis patients, and 12.5±6.8 to 18.0+ 10.7ng/
ml per h in haemofiltration patients. Mean supine blood
pressures did not change during treatment; haemodialysis
from 101 ±4 to 101±5mmHg, haemofiltration from
107±5tol03±7mmHg.
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Fig. I. Plasma ANP concentrations measured by radioreceptor assay
before and after 4h haemodialysis ( • ) or haemofiltration (A) treat-
ment. Significance of effect of treatment was P<0.0\ (haemodialysis)
and P < 0.05 (haemofiltration) by Witcoxon test. Open symbols show
mean changes. Hatched area shows normal range for plasma ANP.
Predialysis plasma ANP concentration was related to
predialysis systolic blood pressure (r = 0.459; P<0.05),
but not to mean blood pressure (r=0.389) or diastolic
blood pressure (r=0.279), nor to plasma renin activity.
No relationships were observed between change in plasma
ANP concentration during dialysis treatment and fall in
weight (r = 0.158), change in plasma renin activity
(r = 0.190), or change in blood pressure (r = 0.219) during
the treatment period. However, a significant linear
correlation was observed between change in ANP during
dialysis treatment and degree of postural blood pressure
decrease after dialysis (Fig. 2) such that those patients
with the greatest reduction in ANP tended to have the
greatest decrease in blood pressure after dialysis.
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Fig. 2. Correlation between postdialysis postural blood pressure fall
(erect mean BP - supine mean BP) and change in plasma ANP concen-
tration during haemodialysis or haemofiltration treatment. Symbols as
in Fig. 1.
Mean plasma ANP concentrations in the three patients
studied sequentially during a 3 h haemodialysis treatment
are illustrated in Fig. 3. ANP fell rapidly during the first
30 min of dialysis, and attained a level of 114 pmol/1 after
3 h treatment. After haemodialysis was stopped, plasma
ANP concentrations recovered rapidly to 83% of the pre-
dialysis value. Weight loss during treatment in the three
patients was 2.2 ± 0.4 kg, with no significant change in the
60 min following dialysis.
Discussion
This study shows that plasma concentrations of biologi-
cally active ANP are greatly elevated in end-stage renal
disease. These data confirm and extend previous reports
employing radioimmunoassay [5-10] which demon-
strated increased concentrations of immunoreactive
peptide. Previous reports have also shown that there is a
reduction in immunoreactive plasma ANP with haemo-
dialysis [6,7] or ultrafiltration [7,8,10]. The present report
demonstrates that biologically active ANP is reduced by
haemofiltration, and that the reduction is comparable to
that achieved by haemodialysis.
Although there is general agreement that plasma ANP
concentrations are reduced during dialysis procedures, it
remains uncertain whether these changes in plasma ANP
are due to volume reduction, fall in atrial pressure,
clearance of the peptide, or a combination of these three
factors. The reduction of plasma ANP by dialysis has
been taken by some to imply that ANP concentrations are
raised in end-stage renal disease purely as a consequence
of volume overload [5,10]. In support of this, there are
some reports of reduction of ANP to the normal range by
haemodialysis. However, these studies have employed
direct radioimmunoassay without prior extraction of
ANP from plasma [9,10], and it is established that direct
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Fig. 3. Sequential plasma ANP concentrations in three patients before,
during, and after 3 h haemodialysis treatment. Mean plasma ANP
concentration is shown.
plasma radioimmunoassay of ANP is inaccurate at
plasma ANP concentrations below 70 pmol/1 [17]. In the
present study, as in previous work employing extraction
of ANP before assay (5-7) plasma levels were still well
above the normal range after dialysis treatment, despite
evidence of hypovolaemia, such as decrease in postural
blood pressure. Similarly, in the study of Walker et al [18],
plasma ANP levels remained in the range 20-120 pmol/1
despite intensive ultrafiltration producing a 3 kg weight
loss.
Blood pressure in patients with end-stage renal disease
is usually volume-dependent, and in this respect a
relationship was present between systolic blood pressure
and plasma ANP concentration, as observed in previous
studies [18]. The correlation was less marked in the
present study than in previous reports; this may be due to
the use of beta-blocker therapy in five of the 20 patients,
since beta-blockade may result in a doubling of plasma
ANP concentrations [19]. A correlation was also observed
(Fig. 2) between reduction in ANP and decrease in pos-
tural blood pressure after dialysis, suggesting a degree
of association between ANP reduction and volume
depletion during dialysis. However, the correlation was
not strong, and there was no relationship between
reduced ANP concentration and reduction in weight or
change in plasma renin activity, implying that other
factors may also contribute to the fall in ANP during
dialysis.
Several lines of evidence indicate that the kidney is an
important site of ANP clearance. In man there is a large
arteriovenous gradient for ANP across the kidney [11],
and acute nephrectomy in rats results in a doubling of
plasma ANP half-life [20]. There is evidence for metab-
olism of ANP in the renal tubule, and recent reports
suggest that ANP is specifically degraded by kidney
neutral endopeptidase [21]. In addition, Maack and col-
leagues have described the existence of biologically silent
clearance receptors for ANP within the kidney, whose
blockade results in increased plasma ANP levels [22].
Consistent with a role for the kidney in clearance of ANP
from plasma, in patients with chronic uraemia but not on
maintenance dialysis an inverse relationship has been
described between plasma ANP and glomerular filtration
rate, but not between ANP and blood volume [8], suggest-
ing that impaired renal removal of ANP contributes to
high plasma levels in uraemia, as is the case for other
polypeptide hormones [13]. It is also conceivable that
elevated ANP concentrations in chronic renal failure
might in turn lead to down-regulation of ANP clearance-
receptors outside the kidney, further increasing ANP
plasma levels.
Since the kidney appears to be important in the
metabolic clearance of ANP, it is possible that plasma
clearance of ANP occurring during dialysis treatments
might also contribute to the decrease in ANP concen-
tration. Haemofiltration is more effective than con-
ventional haemodialysis at clearing substances of high
molecular weight, up to 10 000 daltons [23], and it would
therefore be predicted that for ANP, with a molecular
weight of 3082, haemofiltration would provide a greater
clearance. However, this was not apparent from the
present study, which showed that plasma ANP was
reduced during both treatments to a similar extent. A
recent study [24] has confirmed there is significant though
not major clearance of ANP by both haemodialysis
(25 ml/min) and haemofiltration (46 ml/min), compared
with an overall metabolic clearance rate for ANP in
end-stage renal failure patients of 1.041/min [25].
In addition to decline in clearance by the kidney, a
further reason for the increase in plasma ANP concen-
trations seen in chronic renal failure may be impairment
of cardiac function, independent of fluid volume status.
Increase in atrial pressure, atrial distension, and conse-
quent cardiac ANP release may occur as a consequence of
acute volume expansion [26], with normal cardiac func-
tion, or when cardiac function is impaired, without sig-
nificant volume overload [4]. Cardiac failure is common in
end-stage renal disease, and recent studies have shown
that right and left ventricular end-diastolic pressures at
rest and after exercise are often elevated early in chronic
renal failure, even when patients have no clinical evidence
of congestive heart failure [14], as in the present study.
Hence, occult cardiac dysfunction might contribute
both to elevated plasma ANP concentrations in chronic
renal failure, and to their decrease after dialysis, as
haemodialysis may itself improve ventricular function
[27].
The increase in ANP observed immediately after dialy-
sis while weight remained unchanged in a subgroup of
three patients also argues against simple volume depletion
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being the sole factor causing ANP reduction during dialy-
sis. Both this rapid increase in ANP and the early decrease
at the commencement of treatment (Fig. 3), may be due in
part to clearance of the peptide by the dialysis procedure,
or to fluid redistribution between the extracellular and
intravascular compartments, resulting in rapid changes
in atrial pressure. Right atrial pressure may decrease
dramatically during haemodialysis [24], but the equiv-
alent changes in atrial pressure during the recovery phase
after dialysis are not established.
The concentrations of biologically active ANP in end-
stage renal failure observed in this study are well within
the range required to cause significant arterial vasodila-
tation in man [28], and it is possible therefore that ANP
may play an important and hitherto unsuspected role in
determining vascular resistance in dialysis patients, and
thus in their blood pressure regulation. Nevertheless, it is
likely that vascular tone in these patients will ultimately
depend on a complex interaction between ANP and other
endogenous vasorelaxant mechanisms, and compensa-
tory activation of the sympathetic nervous system and
renin-angiotensin system, determined by plasma volume
changes. In the present study, for example, plasma ANP
concentrations decreased during dialysis, plasma renin
activity increased, but no overall change was observed in
blood pressure. Specific antagonists to ANP will be
needed in order to determine the relative importance of
its contribution to circulatory homeostasis, especially
since reflex effects have been shown to override direct
vasodilatory actions of ANP during infusion of the
peptide [29].
In conclusion, the present study confirms that plasma
concentrations of biologically active ANP may be con-
siderably elevated in end-stage renal disease. They are
reduced by haemodialysis or haemofiltration, but usually
remain above the normal range despite fluid volume
reduction to normal levels or below. Taken together with
the lack of close relationship between decrease in ANP
and indices of volume depletion (weight loss, fall in blood
pressure), this implies that factors other than simple
volume overload contribute to elevation of plasma ANP
in chronic renal-failure patients, and its reduction with
dialysis. These factors may include ANP clearance by the
kidney or dialyser, clinically unsuspected cardiac dysfunc-
tion, or rapid fluid shifts between the intravascular and
extra vascular compartments.
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